Soluble Angiogenic Neoplastic and Fibrotic factor (SANF)

Soluble Angiogenic Neoplastic and Fibrotic factor (SANF) is a soluble isoform of the CD146 (MCAM) protein that acts as a potent driver of pathological processes in the tumor microenvironment and fibrotic tissues [27, 30]. Identified by researchers at the C2VN Institute and developed by Massalia Therapeutics, SANF is secreted by approximately 35-40% of cancer cells and promotes tumor aggressiveness through multiple mechanisms, including the stimulation of angiogenesis, epithelial-to-mesenchymal transition (EMT), and fibroblast-to-myofibroblast transition [27, 32]. It also contributes to immune evasion by increasing the expression of immune checkpoints and is associated with resistance to standard-of-care therapies such as bevacizumab and sunitinib [27, 33]. Unlike membrane-bound CD146, which is essential for normal vascular function and integrity, SANF is primarily linked to disease progression, making it a highly specific therapeutic target [27, 32]. The monoclonal antibody mucizumab (MSL2011) is being developed to selectively neutralize SANF, offering a potential breakthrough for treating aggressive cancers like glioblastoma and various fibrotic diseases [27, 32].

Other names

Soluble CD146sCD146sMCAMSoluble Melanoma Cell Adhesion Molecule

Selective neutralization of the soluble SANF factor without affecting the membrane-bound CD146 isoform